Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct 25:16:4857-4866.
doi: 10.2147/JIR.S431049. eCollection 2023.

Association Between Neutrophil-to-Lymphocyte Ratio and Benign Prostatic Hyperplasia: Results from the TCLSIH Cohort Study

Yanqi Song  1 , Yeqing Gu  2 , Honglei Guo  3 , Honghao Yang  4   5   6 , Xuena Wang  4   5   6 , Hongmei Wu  4   5   6 , Aidi Wang  1 , Haijin Wang  1 , Quan Zhang  1 , Qing Zhang  7 , Li Liu  7 , Ge Meng  6 , Baoshan Liu  1 , Kaijun Niu  4   5   6
Affiliations

Association Between Neutrophil-to-Lymphocyte Ratio and Benign Prostatic Hyperplasia: Results from the TCLSIH Cohort Study

Yanqi Song et al. J Inflamm Res. .

Abstract

Purpose: The prevalence of benign prostatic hyperplasia (BPH) in the general Chinese adult male population has risen sharply over the past few decades. Increasing evidence suggests that inflammation plays an important role in the pathogenesis of BPH. To better understand the role of inflammation in the pathogenesis of BPH, we can use the neutrophil-to-lymphocyte ratio (NLR) because it is a simple and effective marker of inflammation and immunity. This study aims to prospectively investigate the association between NLR levels and the prevalence of BPH in a general Chinese adult male population.

Patients and methods: This study included a total of 15,783 male participants free from BPH at baseline. NLR was measured according to the complete blood count. BPH was defined as total prostate volume (TPV) ≥30 mL, and TPV was determined by transabdominal ultrasonography. Multivariable Cox proportional hazards models were fitted to calculate hazards ratios (HRs) and corresponding 95% confidence intervals (CIs) for BPH risk with NLR levels.

Results: During a median follow-up of 2.7 years, 5078 BPH cases were documented. After adjusting for age, body mass index, smoking, alcohol, education, occupation, income, physical activity, total energy intake, personal and family history of disease, and inflammation markers, the multivariable-adjusted HRs of BPH were 1.00 (reference), 1.08 (95% CIs 0.99, 1.17), 1.10 (95% CIs1.02, 1.19), and 1.12 (95% CIs1.03, 1.21), respectively, for participants with NLR in the first, second, third, and fourth quartiles (P for trend <0.01).

Conclusion: Higher NLR levels were associated with a higher risk of BPH in Chinese adult male population. Our findings support the notion that NLR levels may be an important target for BPH prevention and intervention.

Keywords: benign prostatic hyperplasia; inflammation; neutrophil to lymphocyte ratio; prospective cohort study.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Flow diagram of study participant selection.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Ferlay J, Colombet M, Soerjomataram I, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018;103:356–387. doi:10.1016/j.ejca.2018.07.005 - DOI - PubMed
    1. Ilic D, Misso M. Lycopene for the prevention and treatment of benign prostatic hyperplasia and prostate cancer: a systematic review. Maturitas. 2012;72(4):269–276. doi:10.1016/j.maturitas.2012.04.014 - DOI - PubMed
    1. Ozer K, Horsanali MO, Gorgel SN, Horsanali BO, Ozbek E. Association between benign prostatic hyperplasia and neutrophil-lymphocyte ratio, an indicator of inflammation and metabolic syndrome. Urol Int. 2017;98(4):466–471. doi:10.1159/000448289 - DOI - PubMed
    1. McVary KT, Roehrborn CG, Avins AL, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011;185(5):1793–1803. doi:10.1016/j.juro.2011.01.074 - DOI - PubMed
    1. Chughtai B, Lee R, Te A, Kaplan S. Role of inflammation in benign prostatic hyperplasia. Rev Urol. 2011;13(3):147–150. - PMC - PubMed